<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022657</url>
  </required_header>
  <id_info>
    <org_study_id>13-0427</org_study_id>
    <secondary_id>U01AI106499</secondary_id>
    <nct_id>NCT02022657</nct_id>
  </id_info>
  <brief_title>Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots</brief_title>
  <acronym>DOT-DBS</acronym>
  <official_title>PrEP Adherence Monitoring Using Dried Blood Spots</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Francisco Department of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to define the mean, variance, and dose proportionality
      for tenofovir-diphosphate(TFV-DP) in dried blood spots resulting from 33%, 67%, and 100% of
      daily dosing with 200mg emtricitabine and 300mg of tenofovir disoproxil fumarate (as
      Truvada®). With this information, a model will be established to predict adherence rates to
      TFV-DP using DBS. Forty-eight healthy HIV-uninfected adult participants who are at low risk
      for HIV infection will be randomized to one of 6 sequences consisting of two directly
      observed dosing regimens, 33%/67%, 33%/100%, 67%/33%, 67%/100%, 100%/33%, and 100%/67% with
      each dose regimen lasting approximately 12 weeks, separated by an approximately 12 week
      washout period. DBS will be collected at regular intervals, including during the washout. The
      hypothesis of the study is that levels of TFV-DP in DBS will predict adherence rates in the
      preceding 1-3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada</measure>
    <time_frame>Assessed every 2 weeks during the dosing periods and at steady-state, week 12 for the first dosing period and week 36 for the second dosing period.</time_frame>
    <description>TFV-DP concentrations in DBS respective to dosing regimens of 33%, 67%, 100% of daily dosing.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>PrEP Adherence Monitoring</condition>
  <arm_group>
    <arm_group_label>33%/67%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>33%/100%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>67%/33%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>67%/100%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100%/33%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100%/67%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP</description>
    <arm_group_label>100%/33%</arm_group_label>
    <arm_group_label>100%/67%</arm_group_label>
    <arm_group_label>33%/100%</arm_group_label>
    <arm_group_label>33%/67%</arm_group_label>
    <arm_group_label>67%/100%</arm_group_label>
    <arm_group_label>67%/33%</arm_group_label>
    <other_name>Tenofovir</other_name>
    <other_name>Emtricitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ambulatory 18-50 year old adults. Enrollment will target approximately half women and
             approximately one third African-Americans and one third Latino.

          2. Ability to comply with study procedures, including directly observed dosing visits and
             availability and use of audio-video streaming technology.

        Exclusion Criteria:

          1. Inability to give informed consent

          2. A minimum scalp hair length of 2 cm in the occipital region.

          3. Pregnancy or plan to become pregnant or unwillingness to use birth control

          4. Current breastfeeding.

          5. High risk of HIV-1 infection (for example: sexually active with an HIV infected
             partner; men who have sex with men who may engage in condom-less intercourse with
             HIV-infected partners or partner of unknown status during the study; males or females
             who exchange sex for money, shelter, or gifts; active injection drug use or during the
             last 12 months; newly diagnosed sexually transmitted infections in last 6 months)

          6. Positive screening HIV+ ELISA or suspected acute HIV infection in the opinion of the
             clinician. (example signs and symptoms of acute HIV infection include combinations of
             fever, headache, fatigue, arthralgia, vomiting, myalgia, diarrhea, pharyngitis, rash,
             night sweats, and adenopathy cervical or inguinal)

          7. Positive Hepatitis B (HBV) surface antigen test at screening

          8. Active psychiatric illness, social condition, or alcohol/drug abuse that, in the
             opinion of the investigators, would interfere with study requirements.

          9. History of non-traumatic, pathologic bone fractures

         10. Glomerular Filtration Rate (GFR, creatinine clearance) &lt; 60 ml/min (MDRD equation).

         11. Urine dipstick protein ≥ 2+

         12. Total bilirubin and/or hepatic transaminases (ALT and AST) ≥ 2.5x upper limit of
             normal

         13. Absolute neutrophil count ≤ 1,500/mm3, platelets count ≤ 100,000/mm3, or hemoglobin ≤
             10 g/dL.

         14. Medical condition that alters red blood cell kinetics including hemoglobinopathies or
             active hemolysis.

         15. Any laboratory value or uncontrolled medical conditions that would interfere with the
             study conditions such as, heart disease and/or cancer.

         16. Contraindicated concomitant medications (including investigational agents,
             aminoglycosides, ganciclovir/valganciclovir, chronic high-dose acyclovir/valacyclovir,
             cyclosporine, amphotericin B, foscarnet, and cidofovir, and products with same or
             similar active ingredients as the study medications (Truvada®) including ATRIPLA®,
             COMPLERA®, EMTRIVA®, VIREAD®; or drugs containing lamivudine or adefovir, which are
             close analogs of Emtricitabine (FTC) and tenofovir, respectively).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter L Anderson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco/San Francisco Department of Public Health</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.</citation>
    <PMID>29038282</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>March 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2019</results_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre exposure prophylaxis</keyword>
  <keyword>Dried blood spots</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>52 subjects from 2 sites were analyzed-- CU enrolled only 34.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>100% First, Then 67%</title>
          <description>100% dosing: Dose every day for ~12 weeks 67% holiday dosing regimen: 2 weeks on medication, 1 week off, repeat for ~ 12 weeks 67% intermittent dosing regimen: 2 days on medication, 1 day off, repeat for ~ 12 weeks
67% Intermittent and 67% Holiday dosing combined for analysis.</description>
        </group>
        <group group_id="P2">
          <title>100% First, Then 33%</title>
          <description>100% dosing regimen: dosing every day for ~12 weeks 33% holiday dosing regimen: 1 week on medication, 2 weeks off, repeat for ~ 12 weeks 33% intermittent dosing regimen:1 day on medication, 2 days off, repeat for ~ 12 weeks
33% Intermittent and 33% Holiday dosing combined for analysis.</description>
        </group>
        <group group_id="P3">
          <title>67% First, Then 100%</title>
          <description>67% holiday dosing regimen: 2 weeks on medication, 1 week off, repeat for ~ 12 weeks 67% intermittent dosing regimen: 2 days on medication, 1 day off, repeat for ~ 12 weeks 100% dosing regimen: dosing every day, repeat for ~12 weeks
67% Intermittent and 67% Holiday dosing combined for analysis.</description>
        </group>
        <group group_id="P4">
          <title>67% First, Then 33%</title>
          <description>67% holiday dosing regimen: 2 weeks on medication, 1 week off, repeat for ~ 12 weeks 67% intermittent dosing regimen: 2 days on medication, 1 day off, repeat for ~ 12 weeks 33% holiday dosing regimen: 1 week on medication, 2 weeks off, repeat for ~ 12 weeks 33% intermittent dosing regimen:1 day on medication, 2 days off, repeat for ~ 12 weeks
67% Intermittent and 67% Holiday dosing combined for analysis. 33% Intermittent and 33% Holiday dosing combined for analysis.</description>
        </group>
        <group group_id="P5">
          <title>33% First, Then 100%</title>
          <description>33% holiday dosing regimen: 1 week on medication, 2 weeks off, repeat for ~ 12 weeks 33% intermittent dosing regimen:1 day on medication, 2 days off, repeat for ~ 12 weeks 100% dosing: Dose every day for ~12 weeks
33% Intermittent and 33% Holiday dosing combined for analysis.</description>
        </group>
        <group group_id="P6">
          <title>33% First, Then 67%</title>
          <description>33% holiday dosing regimen: 1 week on medication, 2 weeks off, repeat for ~ 12 weeks 33% intermittent dosing regimen:1 day on medication, 2 days off, repeat for ~ 12 weeks 67% holiday dosing regimen: 2 weeks on medication, 1 week off, repeat for ~ 12 weeks 67% intermittent dosing regimen: 2 days on medication, 1 day off, repeat for ~ 12 weeks
33% Intermittent and 33% Holiday dosing combined for analysis. 67% Intermittent and 67% Holiday dosing combined for analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Arms were combined to be consistent with protocol subject randomization. Subjects were randomized to one of six arms. “Holiday” and “intermittent” groups for 33 and 67% dosing were combined because drug concentrations didn't differ between groups (PMID: 29038282). Combined arms best categorize the study and population.</population>
      <group_list>
        <group group_id="B1">
          <title>All Dosing Regimens</title>
          <description>Baseline characteristics for all 48 subjects included in analysis. Baseline characteristics not stratified based on dosing regimen.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="21" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada</title>
        <description>TFV-DP concentrations in DBS respective to dosing regimens of 33%, 67%, 100% of daily dosing.</description>
        <time_frame>Assessed every 2 weeks during the dosing periods and at steady-state, week 12 for the first dosing period and week 36 for the second dosing period.</time_frame>
        <population>The total number of participants was 48. Each participant was randomized to 2 of 3 dosing regimens for a total of 32 participants each, however 2 participants completed only the first regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>DOT-DBS Dosing 33%</title>
            <description>33%</description>
          </group>
          <group group_id="O2">
            <title>DOT-DBS Dosing 67%</title>
            <description>67%</description>
          </group>
          <group group_id="O3">
            <title>DOT-DBS Dosing 100%</title>
          </group>
        </group_list>
        <measure>
          <title>Steady State Concentrations of TFV-DP for Different Dosing Patterns of Truvada</title>
          <description>TFV-DP concentrations in DBS respective to dosing regimens of 33%, 67%, 100% of daily dosing.</description>
          <population>The total number of participants was 48. Each participant was randomized to 2 of 3 dosing regimens for a total of 32 participants each, however 2 participants completed only the first regimen.</population>
          <units>fmol/punch</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530" spread="159"/>
                    <measurement group_id="O2" value="997" spread="267"/>
                    <measurement group_id="O3" value="1605" spread="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of consenting to study exit (Week 36 or earlier), Max 10 months.</time_frame>
      <desc>AEs were graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, V1.0 Aug 2009 (US Dept HHS, NIH, NIAID) Available from: http://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf
Arms were combined as Truvada was FDA approved for daily use (100% dosing) at the time of study initiation- no arm was considered to be more at risk for AEs than another.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Dosing Regimens</title>
          <description>Overall, the study showed an unremarkable and expected AE profile. At study initiation Truvada was FDA approved for daily dosing (100% daily dosing). Thus, the AE profile was already established for 100% dosing and AE rates in the lower doses (33% and 67%) would not exceed the established rate for daily dosing (100%). This study was not designed to collect new safety data or to update the established AE/Safety profiles for Truvada. Therefore AE data was combined for all dosing regimens since AEs reported per arm/group are not meaningful for research or clinical applications.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Not related to study medication; anxiety requiring hospitalization and medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Symptoms</sub_title>
                <counts group_id="E1" events="83" subjects_affected="41" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abnormal Labs</sub_title>
                <description>Lab, # of Incidents
ALT, 5 AST, 4 Bilirubin, 9 Calcium, 2 Glucose, 16 Hg, 2 Lipase, 4 Other, 7 Phosphorous, 24 Potassium, 3 RBC, 1 Sodium, 1 UA- Protein, 6 UA-RBC, 4</description>
                <counts group_id="E1" events="88" subjects_affected="32" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter Anderson</name_or_title>
      <organization>Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora</organization>
      <phone>3037246821</phone>
      <email>peter.anderson@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

